Nancy R Downing1, Siera Goodnight2, Sena Chae3, Joel S Perlmutter4, Michael McCormack5,6, Elizabeth Hahn7, Stacey K Barton4, Noelle Carlozzi2. 1. 1 Texas A&M College of Nursing, Bryan, TX, USA. 2. 2 University of Michigan, Department of Physical Medicine & Rehabilitation, Ann Arbor, MI, USA. 3. 3 University of Iowa College of Nursing, Iowa City, IA, USA. 4. 4 HDSA Center of Excellence, Washington University at St Louis School of Medicine, St Louis, MO, USA. 5. 5 Department of Pathology, Rowan SOM, Piscataway, NJ, USA. 6. 6 Department of Psychiatry, Rutgers-RWJMS, Piscataway, NJ, USA. 7. 7 Northwestern University Feinberg School of Medicine, Chicago, IL, USA.
Abstract
OBJECTIVE: Knowledge of one's gene status for adult onset conditions provides opportunity to make advance end-of-life (EOL) plans. The purposes of these analyses were to (1) determine the prevalence of EOL plans, including advance directives (ADs) among persons across 3 stages of Huntington disease (HD) and (2) examine factors associated with having ADs in this sample. METHODS: Data are from 503 participants in the HD Quality of Life study. Participants completed an online health-related quality-of-life survey that included questions regarding EOL planning and self-reported HD symptoms. Frequencies were calculated for EOL planning by the HD stage. Bivariate analysis and logistic regression were used to identify variables associated with having ADs. RESULTS: A total of 38.2% of participants stated they had ADs and fewer than half had other EOL plans. Being older, increased HD stage, more years of education, lower anxiety, more swallowing symptoms, and higher meaning and purpose were associated with having ADs. CONCLUSION: The prevalence of ADs in our sample is comparable to the general US population, but surprisingly low, considering the severity and long disease course of HD. PRACTICE IMPLICATIONS: Health-care providers should develop specific interventions early in the disease process to increase ADs in this population.
OBJECTIVE: Knowledge of one's gene status for adult onset conditions provides opportunity to make advance end-of-life (EOL) plans. The purposes of these analyses were to (1) determine the prevalence of EOL plans, including advance directives (ADs) among persons across 3 stages of Huntington disease (HD) and (2) examine factors associated with having ADs in this sample. METHODS: Data are from 503 participants in the HD Quality of Life study. Participants completed an online health-related quality-of-life survey that included questions regarding EOL planning and self-reported HD symptoms. Frequencies were calculated for EOL planning by the HD stage. Bivariate analysis and logistic regression were used to identify variables associated with having ADs. RESULTS: A total of 38.2% of participants stated they had ADs and fewer than half had other EOL plans. Being older, increased HD stage, more years of education, lower anxiety, more swallowing symptoms, and higher meaning and purpose were associated with having ADs. CONCLUSION: The prevalence of ADs in our sample is comparable to the general US population, but surprisingly low, considering the severity and long disease course of HD. PRACTICE IMPLICATIONS: Health-care providers should develop specific interventions early in the disease process to increase ADs in this population.
Entities:
Keywords:
Huntington disease; adult onset conditions; advance directives; palliative care
Authors: N E Carlozzi; N R Downing; M K McCormack; S G Schilling; J S Perlmutter; E A Hahn; J S Lai; S Frank; K A Quaid; J S Paulsen; D Cella; S M Goodnight; J A Miner; M A Nance Journal: Qual Life Res Date: 2016-07-08 Impact factor: 4.147
Authors: Jennifer Hagerty Lingler; Karen B Hirschman; Linda Garand; Mary Amanda Dew; James T Becker; Richard Schulz; Steven T Dekosky Journal: Am J Geriatr Psychiatry Date: 2008-08 Impact factor: 4.105
Authors: S Daack-Hirsch; M Driessnack; A Hanish; V A Johnson; L L Shah; C M Simon; J K Williams Journal: Clin Genet Date: 2013-05-03 Impact factor: 4.438
Authors: Elizabeth A McCusker; David G Gunn; Eric A Epping; Clement T Loy; Kylie Radford; Jane Griffith; James A Mills; Jeffrey D Long; Jane S Paulsen Journal: Neurology Date: 2013-08-21 Impact factor: 9.910
Authors: N E Carlozzi; N R Downing; S G Schilling; J-S Lai; S M Goodnight; J A Miner; S A Frank Journal: Qual Life Res Date: 2016-05-03 Impact factor: 4.147
Authors: Marina R Ekkel; Marja F I A Depla; Els M L Verschuur; Ruth B Veenhuizen; Cees M P M Hertogh; Bregje D Onwuteaka-Philipsen Journal: BMC Palliat Care Date: 2021-01-12 Impact factor: 3.234
Authors: Leonard L Sokol; Jonathan P Troost; Benzi M Kluger; Allison J Applebaum; Jane S Paulsen; Danny Bega; Samuel Frank; Joshua M Hauser; Nicholas R Boileau; Colin A Depp; David Cella; Noelle E Carlozzi Journal: Ann Clin Transl Neurol Date: 2021-07-20 Impact factor: 4.511